Targeted Rna Sequencing Market Overview:
The Targeted Rna Sequencing Market Size is USD 4,554.59 Million in 2022. It is projected to reach USD 8,684.17 Million by 2030, indicating a CAGR of 8.5% during the forecast period. Targeted RNA sequencing is a cutting-edge technology that enables researchers to selectively analyze and quantify RNA molecules of interest. By focusing on specific RNA targets, this technique offers a more cost-effective and efficient alternative to whole transcriptome sequencing.
Targeted RNA sequencing, also known as capture-based RNA sequencing or gene panel sequencing, offers a solution to these challenges. By focusing on a defined set of RNA targets, researchers can achieve high sequencing depth and sensitivity while reducing costs and data complexity.
Market Segmentation:
By Technology
· Exome Sequencing
· Enrichment Sequencing
· Amplicon Sequencing
By Application
· Biomedical Research
· Plant & Animal Sciences
· Drug Discovery
· Others
By End User
· Academic Research
· Hospitals & Clinics
· Pharma & Biotech Entities
· Others
Key Players in the Targeted RNA Sequencing Market
· Thermo Fisher Scientific
· Roche Holdings
· Illumina Inc.
· Oxford Nanopore Technologies
· Agilent Technologies
· QIAGEN
· DNASTAR Inc.
· Bio-Rad Laboratories Inc.
· BGI
· PierianD
Click Here To Know More About: Targeted RNA Sequencing Market Research
Regional Analysis:
The targeted RNA sequencing market in North America is driven by a robust research infrastructure, significant investments in genomics research, and the presence of major pharmaceutical and biotechnology companies. European countries have a strong emphasis on genomics research and personalized medicine, contributing to the growth of the targeted RNA sequencing market in the region. Also, The Asia Pacific region is witnessing significant growth in targeted RNA sequencing due to increasing research activities, rising investments in genomics research, and a growing focus on personalized medicine.
Contact us:
Consegic Business intelligence Pvt Ltd.
Contact no: (US) (505) 715-4344
Email: [email protected]
About Author
